Bengaluru | August 13, 2025 — Medical technology startup Cureous Labs has raised ₹1.66 crore in its pre-Series A seed round, led by Inflection Point Ventures (IPV) with participation from Anthill Ventures, to launch their flagship product, Eturnal, in India.
What is Eturnal?
Developed by Ashish Mohandas, Eturnal is an automated patient-repositioning device designed to prevent bedsores—an issue that affects millions of bedridden patients. It not only improves patient care but also enhances efficiency for nurses and caregivers. The device is priced at one-fifth the cost of global alternatives.
The startup reports over 30,000 hours of machine usage and has completed more than 14,000 automated repositioning sessions, showcasing strong early traction and reliability.
Roadmap & Impact
With fresh capital, Cureous Labs will:
- Begin manufacturing Eturnal, building initial inventory
- Expand sales and business development teams
- Launch their first disinfection centre
- Complete product safety certifications
- Expand their portfolio to serve B2B healthcare customers, such as hospitals, nursing homes, and rehabilitation centres
Why This Matters
Bedsores cause prolonged hospital stays, suffering, and increased healthcare costs. Eturnal addresses these issues head-on with technology that’s affordable, scalable, and proven. By delivering automation at one-fifth the price of alternatives, Cureous is not only innovating they’re democratizing critical patient care.
Follow StartupByDoc for more inspiring stories of founders building impactful medtech solutions in India and beyond.